We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
+$100M
Cap. Flow %
2.31%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
2 Miscellaneous 3.74%
3 Financials 0.54%
4 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
1
AstraZeneca
AZN
$252B
$231M 5.31%
1,749,500
-100,500
-5% -$13.2M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$137B
$223M 5.13%
793,000
+247,400
+45% +$66.2M
ARGX icon
3
argenx
ARGX
$64B
$217M 4.98%
572,500
+396,500
+225% +$128M
ELV icon
4
Elevance Health
ELV
$85.5B
$213M 4.89%
441,000
+41,600
+10% +$20.6M
AVTR icon
5
Avantor
AVTR
$9.86B
$207M 4.75%
6,652,700
+984,400
+17% +$30.7M
LLY icon
6
Eli Lilly
LLY
$1.05T
$198M 4.54%
+610,000
New +$183M
HUM icon
7
Humana
HUM
$46.3B
$193M 4.43%
412,300
+213,400
+107% +$95M
UTHR icon
8
United Therapeutics
UTHR
$22.1B
$171M 3.93%
725,600
+6,654
+0.9% +$1.35M
JNJ icon
9
Johnson & Johnson
JNJ
$646B
$160M 3.67%
900,200
+546,200
+154% +$97.3M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$148M 3.4%
1,856,900
+725,500
+64% +$68.7M
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.7B
$143M 3.28%
1,467,600
+307,600
+27% +$28.4M
ARVN icon
12
Arvinas
ARVN
$600M
$141M 3.24%
3,355,623
+440,323
+15% +$22.1M
XBI icon
13
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$139M 3.2%
1,875,000
+1,435,000
+326% +$108M
MCK icon
14
McKesson
MCK
$104B
$127M 2.91%
388,800
+199,300
+105% +$63.8M
UNH icon
15
UnitedHealth
UNH
$353B
$124M 2.86%
242,200
-17,400
-7% -$8.74M
ABBV icon
16
AbbVie
ABBV
$451B
$116M 2.65%
755,000
-711,100
-49% -$109M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.74B
$105M 2.41%
5,450,000
+626,600
+13% +$10.4M
CTLT
18
DELISTED
CATALENT, INC.
CTLT
$102M 2.35%
955,000
+173,000
+22% +$17.6M
ZNTL icon
19
Zentalis Pharmaceuticals
ZNTL
$360M
$101M 2.31%
3,585,881
+408,882
+13% +$10.8M
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$97.3M 2.23%
550,000
+450,000
+450% +$64.8M
BSX icon
21
Boston Scientific
BSX
$67.9B
$94.1M 2.16%
2,525,000
+1,328,900
+111% +$54.1M
BIIB icon
22
Biogen
BIIB
$32.3B
$89.8M 2.06%
440,566
+75,566
+21% +$15.4M
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.52B
$88.3M 2.03%
1,479,500
+610,500
+70% +$37.6M
ACHC icon
24
Acadia Healthcare
ACHC
$2.66B
$70M 1.61%
+1,035,000
New +$72.2M
NTLA icon
25
Intellia Therapeutics
NTLA
$1.8B
$58.2M 1.34%
1,125,194
+735,119
+188% +$37.3M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management's Q2 2022 filing shows 10 new, 31 increased, 13 reduced and 20 closed positions. Its largest new stake was Eli Lilly: 610,000 shares worth $198M. The largest sale was Merck, an estimated $194M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.